3-Methyladenine (3-MA)

For research use only. Not for use in humans.

目录号:S2767 别名: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

CAS No. 5142-23-4

3-Methyladenine (3-MA, NSC 66389) 是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用(加热助溶)

规格 价格 库存 购买数量  
RMB 579.66 现货
RMB 3010.37 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的3-Methyladenine (3-MA)发表文献474篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 3-Methyladenine (3-MA, NSC 66389) 是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用(加热助溶)
靶点
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
体外研究

3-MA对Vps34轻微的偏向性可能是由于Vps34中某个特异性的疏水环形结构可以环绕在3-MA的3-甲基基团外面造成的[1] 。据报道对于正常培养和饥饿处理的癌细胞3-MA都能引起细胞死亡。3-MA还可以不通过抑制自吞噬来抑制细胞迁移和入侵,这表明3-MA 除了抑制自吞噬之外还有其它生物功能。3-MA可以造成半胱天冬酶依赖的细胞死亡,这一功能与它对自吞噬的抑制无关。用5mM 3-MA处理葡萄糖饥饿Hela细胞可降低gfp-lc3阳性细胞比例至23%。3-MA处理细胞12到48小时内 LC3-I 的水平上升而LC3-II 水平下降。LC3-I转为为 LC3-II 的过程被3-MA抑制了。 2.5 mM 或5 mM 3-MA 处理HeLa 细胞一天并不影响细胞存活率, 而 10 mM 3-MA 处理一天会造成细胞存活率下降25.0% 。 2.5, 5 或 10 mM 3-MA 处理细胞两天分别使细胞存活率下降 11.5%, 38.0% 和79.4% 。3-MA 降低细胞存活率的作用具有时间和剂量依赖特性。3-MA 明显缩短nocodazole诱导的前中期阻断时间[2]。3-MA 通过抑制自吞噬来抑制SU11274诱导的细胞死亡[3]。 在野生型MEF细胞中延长 3-MA处理时间 (最多 9 小时) 明显造成 LC3 I 到 II 转换。延长 3-MA处理时间会明显增加GFP-LC3的聚集而wortmannin不具有此功能。3-MA介导的LC3 转换和游离 GFP 释放是ATG7依赖的。 3-MA处理会导致 p62 蛋白水平明显升高。即使在Atg5−/− 的MEF细胞中3-MA 也会使p62 水平升高,就像在DOX介导的ATG5缺失的细胞中一样 。3-MA以不同方式抑制 I 型和 III型 PI3K。与野生型细胞相比,在Tsc2−/−细胞中3-MA诱导的 LC3 I 到 LC3 II 转换过程大幅下降。3-MA会破坏mTOR复合物1的拮抗自吞噬功能[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmzcW0> MnLLNog> MVnEUXNQ NVvBPY9OemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= MWiyOVcyPjV4MR?=
A549  NY\VNmx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL0ZXhPO22P MV[ybC=> Mme2SG1UVw>? M3r4RpJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? NUPhNHczOjV5MU[1OlE>
95D NH7PdIJCeG:ydH;zbZMhSXO|YYm= NILScVY2dU1? M{nRWFJp NHrqR4dFVVOR M2fHcIlvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= M{j6N|I2PzF4NU[x
A549  M33W[GFxd3C2b4Ppd{BCe3OjeR?= MkPDOY1O M37sVVJp NIC0ZoZFVVOR MVXpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? M2e4WlI2PzF4NU[x
NBL-W-S  Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInvVm0ydU1? NH3PWZQ3cA>? NYr3b4Fp\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=> MlzKNlU{OjN{MkK=
NBL-W-S  MVHBdI9xfG:|aYOgRZN{[Xl? MoTPNY1O MUe2bC=> NVfScG55cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhT0GQVD22NS=> NEfvTZozPTN{M{KyNi=>
A2780cp  Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPLb3gydU1? M3zDVlFp MWHpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NHrxSGszPTN{Mk[5OC=>
A549  MYnGeY5kfGmxbjDBd5NigQ>? MVK1cW0> MnjFNog> M17X[pN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> M{PWWFI2Ojh3NkK4
H157 MVnGeY5kfGmxbjDBd5NigQ>? NHTLU|E2dU1? M1vlb|Jp NVPYWGFHe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK NFPn[3AzPTJ6NU[yPC=>
MDR NXnnVVFpSXCxcITvd4l{KEG|c3H5 MWSxNI1O M1HUc|Zp NF;Oeod{fHKnbnf0bIVveyC2aHWgdI94\XJib3[gZY51cWOjbnPldkBlenWpcx?= Mm\JNlUxOTl5MEG=
HT-29  MmTxRZBweHSxc3nzJGF{e2G7 NH;aS|cydU1? Mn7uOFhp MnzVSG1UVw>? MknG[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NGLzb4wzPDh2MkG1PC=>
Microglia  MmXJRZBweHSxc3nzJGF{e2G7 MYq1cW0> M2LYVFI1cA>? M{fneoRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MnziNlQ5OTh4MEG=
A2780cp MkHHRZBweHSxc3nzJGF{e2G7 NWryemd[Oi53bV2= MmT0NYg> NWTjSHBq\GSKMl:= M3HtcYVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> MVeyOFgyPzl2Nh?=
HepG2 NUKwNpFYTnWwY4Tpc44hSXO|YYm= NXHjPJVRPW2P M2D1dVRp M2C2eolv[3KnYYPld{BJVCC{ZXzlZZNm NYLXOIdxOjR5MUO1PFc>
A549 MYPBdI9xfG:|aYOgRZN{[Xl? MX[1cW0> M3fIelQ5cA>? NV\QXpBJ\GWlcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHyg[IVifGhiYX7kJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKGOjc4Dhd4UuOyxiQnXjcIlvNTFiYX7kJGxEOy2LSR?= M37ReFI1PzB4M{Cz
U2OS M3;nU2Fxd3C2b4Ppd{BCe3OjeR?= MlK4NVBuVQ>? MXmyOIg> M4\4dYlvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? MoC4NlQ3OzlyMUO=
Saos-2 M1PnOmFxd3C2b4Ppd{BCe3OjeR?= M1;sW|ExdU1? MUmyOIg> NXG5cGpzcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 M2nnfFI1PjN7MEGz
A549 MlS5RZBweHSxc3nzJGF{e2G7 M1HMVVExdU1? MnThOFhp MlPZZYNk\WyncnH0[ZMhfGinIILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JHBVYA>? MYeyOFYzPjd{Mh?=
HCT116  MkfVRZBweHSxc3nzJGF{e2G7 MV[1cW0> MoGwNlRp NFG0TXlmdmijbnPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZZBq\2WwaX6= MmPYNlQ3OjZ3MkK=
HGC-27 M3vrcmZ2dmO2aX;uJGF{e2G7 MlLjNVBuVQ>? MmDKNYg> M3LZOIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O|IHL5JHJCTDByMTDvdkBOUy1{MkC2 NXzN[mJuOjR2MU[zOFk>
U2OS  M3XnVmZ2dmO2aX;uJGF{e2G7 NV\US|hoOC53L{HtUS=> NXXMRnI3PDiq NHfaSGpqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MnPwNlQ{PTh|NEK=
MG-63 MmPiSpVv[3Srb36gRZN{[Xl? NVvFS4ZEOC53L{HtUS=> M4XRRVQ5cA>? MVjpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MUiyOFM2QDN2Mh?=
MG-63 Ml:1RZBweHSxc3nzJGF{e2G7 MUWwMlUwOW2P NXLDbWdVOzKq MkW5[Y5p[W6lZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?= M1nzVlI1OzV6M{Sy
MG-63 NXv5OnA{SXCxcITvd4l{KEG|c3H5 M3TKRVExdU1? M1fz[lEzcA>? M1PJcoVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ MXuyOFM2QDNyMR?=
NTUB1 M{\W[WFxd3C2b4Ppd{BCe3OjeR?= MV21cW0> NY[zdHlVOS53aB?= MoLOdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NHq3ZlYzPDN2OUG3Oi=>
T24 MWTBdI9xfG:|aYOgRZN{[Xl? MlXzOY1O MWOxMlVp M2jzTJBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? Mnq1NlQ{PDlzN{[=
SGC-7901  MnjhRZBweHSxc3nzJGF{e2G7 MkTNNo1O M2e3W|Fp MmDSbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? MVSyOFMzOTN2MB?=
SMMC-7721 NV\1VXA6SXCxcITvd4l{KEG|c3H5 Mle3No1O M3vMO|Fp NVvEO3VTcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NVHGcnIyOjR|MkGzOFA>
ECSCs  M371R2Fxd3C2b4Ppd{BCe3OjeR?= MUCxNI1O M3[xdFRp NXm4SY9T\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? NIXhO2MzPDNzOUGwPS=>
MCF-7  NELzVVFHfW6ldHnvckBCe3OjeR?= NGfm[JYyOG2P NH7jZoMzPGh? NG[wSWNqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgZ4hmdW:2aHXyZZB6KGS{dXfz M17UOFI1OzF3NUe4
UOK257 M1X4dWFxd3C2b4Ppd{BCe3OjeR?= MY[1cW0> NXPzSHlDO2h? MX7lcohidmOnczDwZYNtcXSjeHXsMY1m\GmjdHXkJIFxd3C2b4Ppd:Kh M1;CNlI1OzB3NkC0
ACHN-5968 NYPLVItKSXCxcITvd4l{KEG|c3H5 NVn5UpNIPW2P NE\pUmE{cA>? M4rQdIVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? Mn\xNlQ{ODV4MES=
Huh7 Mmq3RZBweHSxc3nzJGF{e2G7 MViycW0> M3XBVVEzcA>? MlXySG1UVw>? MnvHbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= MnflNlQzQTd|MEC=
Hep3B M4ThZ2Fxd3C2b4Ppd{BCe3OjeR?= MkPuNo1O NXjyTIJMOTKq M2C4bWROW09? MnrtbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= NV:5eHBSOjR{OUezNFA>
RKO NYnVcmJ5TnWwY4Tpc44hSXO|YYm= NIq0SWEzdU1? NWLU[GxYOWh? NVrXcpRiTE2VTx?= NGXiUoVmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> M1i1dlI1OjlzN{e3
HepG2 E47 NFPyT4JHfW6ldHnvckBCe3OjeR?= MUOyMlVuVQ>? NVnlT2d{PDiq NFfQdZZqdmO{ZXHz[ZMhfGinIITvfIlkcXS7IH;mJGFCNCCEU1:sJIFv\CCFQ3y0 NW\ld492OjR{N{O3N|g>
LoVo  M1LFUWFxd3C2b4Ppd{BCe3OjeR?= NFzzXJA2dU1? M33zelQ5cA>? Mnjt[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? NG\5RW0zPDJyMUixNi=>
WiDr Ml7NSpVv[3Srb36gRZN{[Xl? M2ry[|ExdU1? NVX3fohxOWh? MXLpcohq[mm2czDQR2JNNWmwZIXj[YQhVEN|IFnJJIV5eHKnc4Ppc44> NXfJZ3VZOjRzOUC0PFk>
H1299  NFu5eGtHfW6ldHnvckBCe3OjeR?= M4[0T|ExdU1? NXO5TGtsPGh? NXu5cFZicW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? NH7MRowzPDF5M{KwPC=>
H460 MofNSpVv[3Srb36gRZN{[Xl? NXG1dFdZOTCvTR?= NH;4S2I1cA>? NWjDT3U3cW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? MmXmNlQyPzN{MEi=
A549 NX3GOIFLTnWwY4Tpc44hSXO|YYm= Mo[2NVBuVQ>? NH:x[GE1cA>? MYPpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBqenKjZHnheIlwdg>? NF7BWnIzPDF2MkezOS=>
Hep3B NVnxb|U4SXCxcITvd4l{KEG|c3H5 NXj6NVdSPW2P M12wbVI1cA>? NFrvfWNifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> NEHuZ|AzPDB4Nk[5Ny=>
SMMC-7721 MWTBdI9xfG:|aYOgRZN{[Xl? M4naeVVuVQ>? MYSyOIg> M1LuTYF1fGWwdXH0[ZMhXE6ILd8xJJBzd3SnY4Tpc44h[WejaX7zeEB{\XK3bTDzeIFzfmG2aX;uMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NX\GXmVSOjRyNk[2PVM>
HO8910 NEH6bWNCeG:ydH;zbZMhSXO|YYm= MknVNVBuVQ>? M4SwdVEzcA>? NWf3dnlY\W6qYX7j[ZMhSjF7LXnu[JVk\WRiYYDvdJRwe2l? NHHYNoozOzl6M{[xNC=>
MCF7 MUnGeY5kfGmxbjDBd5NigQ>? MYO1cW0> MnvCNlRp Mn3pbY5kemWjc3XzJGN2VyCrbnT1Z4VlKGOnbHyg[IVifGh? MV[yN|k3OjZ{OR?=
HONE-1  MYnGeY5kfGmxbjDBd5NigQ>? M2SxSFVuVQ>? NVTIb5hpOWh? MW\y[ZBz\XO|ZYOgOpIudWWmaXH0[YQhWk:VIIDyc4R2[3Srb36= MnXFNlM5QTJ|NUi=
HeLa M3;3bGZ2dmO2aX;uJGF{e2G7 M4rkNVExdU1? MUGybC=> Mnfvd5VxeHKnc4Pld{BNSzNiSVmg[ZhxemW|c3nzc44> M3LoZlI{QDZ2N{O4
HepG2 NGXnUHRHfW6ldHnvckBCe3OjeR?= NGnZRY0yOG2P MnHONlRp Ml;pbY5pcWKrdIOgd4lVUUeDUj2gZY5lKEiEU2OtbY5lfWOnZDDheZRweGijZ4m= NXfSTYtsOjN6MUewOFA>
SH-SY5Y M336cWZ2dmO2aX;uJGF{e2G7 Mmj0NY1O MmDKNlRp M2\5S4lvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDUU2NR NXPY[VNROjN5NEOxOFg>
SH-SY5Y MYTBdI9xfG:|aYOgRZN{[Xl? M4TQdFVuVQ>? MV:xbC=> MWjhZo9tcXOqZYOgZ4Vt[XO2cn;sJI5mfXKxcILveIVkfGm4ZTDl[oZm[3R? MnzqNlM3OTl|OUW=
PC12  Ml7NSpVv[3Srb36gRZN{[Xl? MUexNI1O NF3PcWkzPGh? NHfjPYh4[XSnch?= MX9CpIlvcGmkaYTzJINpgW2xdIL5dJNqdi2uaXvlJJBzd3SnYYPvcYFtKGGldHn2bZR6Ng>? M4XRVVI{PjB|OUe5
OV2008 NFr6[mVCeG:ydH;zbZMhSXO|YYm= NF3pTJo2dU1? MW[yOIg> M4jv[4Nwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| Ml[yNlM2QTJ{OEG=
A2780 NV7Bc|cySXCxcITvd4l{KEG|c3H5 M{XqN|VuVQ>? NILHNJAzPGh? NWLrd2ZF[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= MXKyN|U6OjJ6MR?=
Saos-2  NIj4bmFCeG:ydH;zbZMhSXO|YYm= MlXGNY1O M2TVblk3cA>? MkXRbY5kemWjc3XzJINmdGxiZHXheIghcW6mdXPl[EBjgSCSQ2i= NFrjTpczOzV4M{G3NS=>
1321N1 MmTVR5l1d3SxeHnjbZR6KEG|c3H5 MkjVOY1O MXKyOIg> NVPXUFFqeHKxdHXjeJMh[2WubDDh[4FqdnO2IGDDUk1qdmS3Y3XkJJRwgGmlaYT5 NWrpRlA1OjN3MkWyOlU>
SH-SY5Y MlXMR5l1d3SxeHnjbZR6KEG|c3H5 MXG1cW0> M1LONFI1cA>? NWfKc|Q3cW6lcnXhd4V{KFCFTjD0c5hq[2m2eR?= M1HFOlI{PTJ3Mk[1
HT-29  MoHQSpVv[3Srb36gRZN{[Xl? Moe0NY1O MVy0PE86Pmh? NIG1WnlqdmirYnn0d{BCVVCNIHnu[JVk\XNiYYX0c5Bp[WerYzDj[YxtKGSnYYTo MoXKNlM2ODh{N{K=
OR6 M2D2dmZ2dmO2aX;uJGF{e2G7 MlzPNVBuVQ>? NGjzSlU4Omh? NWDDSY1Ue3WycILld5NmeyCKQ2[gdoVxdGmlYYTpc44h[W6mIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MlHRNlM{QTV6N{W=
Hela  M4TYSWZ2dmO2aX;uJGF{e2G7 MWO1cW0> NY[1TVlWOjSq MnnjbY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=> NHK0XpczOzN7NU[3PS=>
MCF-7  MYTGeY5kfGmxbjDBd5NigQ>? NXPKRWtvPW2P M1rQPFI1cA>? M4eyTYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NH3DbJEzOzN7NU[3PS=>
HUVECs MY\GeY5kfGmxbjDBd5NigQ>? NXHPfWV2O22P M2r4SFI1cA>? MlnlZoxw[2u|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>? MVeyN|M2QDl{OB?=
T24 MoTZSpVv[3Srb36gRZN{[Xl? MmXFNVBuVQ>? M1OwdlFp MnP2doVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?= NVz2U2lkOjN|NUSwPFA>
U251MG  NYfNVmNlTnWwY4Tpc44hSXO|YYm= MnPuN41O MXGxbC=> MWLzeZBxemW|c3XzJGxEOy2LSTDwdo91\WmwIHX4dJJme3Orb36= M1TaUlI{OzN6NkG4
GTL-16  NGT6SIhCeG:ydH;zbZMhSXO|YYm= NUC5UZcxPW2P NECwZ2kzPGh? M2jQ[pJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYOgZ49ueGG{ZXSgeI8h[2WubIOgeJJm[XSnZDD3bZRpKE2HVDDpcohq[mm2b4Lz Mnr0NlM{OTN2OUC=
T-47D MYPGeY5kfGmxbjDBd5NigQ>? NIjyeIkyOG2P M13rT|Jp Ml\EbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN? NIW1TWszOzNyMECyOi=>
PaCa44 MWfBdI9xfG:|aYOgRZN{[Xl? M1TOflIvPW2P NFTDWYIycA>? NGriNoFz\WS3Y3XzxsBo\W6rcHnuMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NFPMXmYzOzF{NEGxNi=>
MDA-MB231 NH;Bb4lHfW6ldHnvckBCe3OjeR?= MmfiOY1O NG\tZpIycA>? M2fJfYlv[3KnYYPld{Bz\XO4ZYLheJJwdC2vZXTpZZRm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> MX6yN|A5QDh3MB?=
HeLa Ml:wRZBweHSxc3nzJGF{e2G7 NHnnVGcyOG2P M1vNeVJp Mm\0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2bXXueEB4cXSqIGDFTS=> NH20[VEzOzByMEGzOS=>
SK-HEP-1 MYjBdI9xfG:|aYOgRZN{[Xl? M1jKSFExdU1? MVKxbC=> M4[4d5Bzd3SnY4TzJIFo[Wmwc4SgZZV1d3CqYXf5JIFv\CCrbnT1Z4V{KGGyb4D0c5NqeyCrbjDieYZidGmwLYTy[YF1\WRiY3XscJM> NVPXS3lEOjJ6NUi2OFk>
HepG2 M{LCeWFxd3C2b4Ppd{BCe3OjeR?= NXXTSJJ6O22P M2S5XFVp M{\YT5Jm\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDRSJM> NEe4WnIzOjh|NkW5OS=>
MCF-7  NWfCXGpXTnWwY4Tpc44hSXO|YYm= MkXFNo1O MmjPNlRp NGmxenRqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCWTdMg MWOyOFk4ODZ5Nh?=
MDA-MB-231 NIP2XmNHfW6ldHnvckBCe3OjeR?= MkexNo1O NVHJZpVHOjSq NX[0e3NOcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NEnkTIozPDl5ME[3Oi=>
MCF-7  M4fudWZ2dmO2aX;uJGF{e2G7 MUeycW0> MkOxOFhp NUTseYlReHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq M{jvTVI1QTdyNke2
MDA-MB-231 NHjQV2JHfW6ldHnvckBCe3OjeR?= M3nvSVJuVQ>? M3LvWVQ5cA>? MXrwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg> MXOyOFk4ODZ5Nh?=
PANC-1  M1njUWFxd3C2b4Ppd{BCe3OjeR?= MUCxcW0> MlrPOFhp NXzJRZN4TE2VTx?= NHLuPWJmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MkLiNlQ5PDJzNUi=
MDA-MB 231 MVTBdI9xfG:|aYOgRZN{[Xl? M2q4eFVuVQ>? NILIW5UxNjWq M376S41w\HWuYYTld{BVd2OxbXnuxs7DqGmwZIXj[YQh[XCxcITvd4l{ MmrpNlQ5OzB5OEG=
Microglia  MULBdI9xfG:|aYOgRZN{[Xl? MXK1cW0> MoL0NlRp MUDk[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NGO5dpEzPDhzOE[wNS=>
A2780cp NF;MWGlCeG:ydH;zbZMhSXO|YYm= M2f6[VIvPW2P Mli0NYg> NVzXVW4z\GSKMl:= MV;lcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo MU[yOFgyPzl2Nh?=
HepG2 NUfOZ3FYTnWwY4Tpc44hSXO|YYm= M3TyVlVuVQ>? MVS0bC=> NIC3W3VqdmO{ZXHz[ZMh[2WubIXsZZIhdGW4ZXzzJI9nKEiOwrC= MkDsNlQ4OTN3OEe=
U2OS NVjHZYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL3VoIyOG2P M2rwNVI1cA>? NGLMWIxqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUBFd3h? MkLYNlQ3OzlyMUO=
HCT116 NUXrTmlESXCxcITvd4l{KEG|c3H5 M4\ZRlVuVQ>? MXiyOIg> NGWycYVFVVOR NHrtO2hmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg> NV7PW48{OjR4Mk[1NlI>
MCF-7  NWq2VG5tSXCxcITvd4l{KEG|c3H5 M4j4d|AvOW2P MXO2bC=> MlPr[Y5p[W6lZYOgd4lzfGmwb3ytbY5lfWOnZDDhdI9xfG:|aYO= NGTDXmYzOjd3MUm4PS=>
PC-3  NIDqXolCeG:ydH;zbZMhSXO|YYm= NGG3OIwzdU1? MX6ybC=> M2TxW4lv[3KnYYPld{BQWklvaX7keYNm\CClZXzsJIRm[XSq M1PrclIzPzR3NUiw
U251  M3[3O2Fxd3C2b4Ppd{BCe3OjeR?= NFvyd3Y2dU1? NWXVWXVLOjSq NGjLTJRqdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq NELqTnIzOjV5OUe4PC=>
HeLa  NITLXnRCeG:ydH;zbZMhSXO|YYm= MmH3OY1O M17vd|I1cA>? MYPpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= NFrrdmMzOjV2NUGyPC=>
A549 NWTIbldbTnWwY4Tpc44hSXO|YYm= NW\GZmVuOC5zbV2= NH;md|IzPGh? NX7NbI9Fe3WycILld5NmeyCVVUGxNlc1NWmwZIXj[YQh[2WubDDk[YF1cA>? MX2yNlQ3Pjl4MB?=
pDCs NH;4[VlHfW6ldHnvckBCe3OjeR?= NFHTcpcyOG2P NETPfpgxNjWq MkToxsBz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gTWZPNc7zIHL5JJN{Wk6DNEC= NXjCOVlHOjJ|OU[1PVk>
BGC-823 NHrsfWNHfW6ldHnvckBCe3OjeR?= Mo[0OY1O MYiybC=> MoOzbY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> Ml:yNlI{OjJzNUK=
U937 NV7SZo1STnWwY4Tpc44hSXO|YYm= MoezNo1O NVrWTWFtOTKq M2LUWYRm[3KnYYPld{B1cGViYYX0c5Bp[We7IILheIlwyqB? MUSyNlE2PTF3MB?=
Marc-145 Mmm3SpVv[3Srb36gRZN{[Xl? MY[1cW0> NHnPVnkyOi9{ND:zOog> NWrJW4IzemWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u NH70XlczOjFzOUmwNC=>
HBx  M17hV2Fxd3C2b4Ppd{BCe3OjeR?= MW[xNI1O MnPwOFhp MXPEUXNQ MXXpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> MorkNlIxOjByN{i=
MCF-7 M1XZcGZ2dmO2aX;uJGF{e2G7 NXPhcFRlOTCvTR?= M2rqbFQ5cA>? MWjicI9kc3NiYYX0c5Bp[We7IHnu[JVk\WRiYomgZo9zfGW8b33pZi=> MmjrNlE6OzF7M{e=
RMPI8226  Mnz5SpVv[3Srb36gRZN{[Xl? MmjCOY1O MXqxbC=> NHvxRZB{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w NHvMWHgzOTlzNU[yNC=>
PC12/TetOn NXzzdFZ2TnWwY4Tpc44hSXO|YYm= NIftdmcxNjFxMX3N MYexPIg> MknQcIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? MmXmNlE6ODZ4NUm=
HeLa  MlT0R5l1d3SxeHnjbZR6KEG|c3H5 MX6ycW0> M3;XflI1cA>? NVvTUHU3cW6qaXLpeIV{KHSqZTDjfZRwfG:6aXPpeJkhd2Zic3nsbYJqdmmwIITvJGhmVGFiY3XscJMv M1H5blIyQDd3M{i1
Jurkat MXfGeY5kfGmxbjDBd5NigQ>? NWDLbFh6OTCvTR?= M2XkSVFp NXrDe5Zq\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> M2LiVVIyQDZ2MEO3
K562 NIDOWW9HfW6ldHnvckBCe3OjeR?= NGjLeXcyOG2P NX;PZVgxOWh? MoTm[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= M4HBNVIyQDZ2MEO3
Nara-H NWfiUIRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe1cW0> MkDaOFhp M3jTS4VvcGGwY3XzJJRmdXOrcn;sbY12e22nZHnheIVlKHO3cIDy[ZN{cW:wIH;mJG5iemFvSDDj[YxtKHC{b3zp[oVz[XSrb36= M4\SeVIyQDB3MEOz
HUVECs MV;GeY5kfGmxbjDBd5NigQ>? NYqx[4NvOTCvTR?= M4jJZVAvPWh? MmHJ[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= MmLiNlE1Pjh3OUK=
HepG2 MVrBdI9xfG:|aYOgRZN{[Xl? MU[ycW0> NHTxe4kycA>? MoPk[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NGHTV2szOTR3M{[5NS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
体内研究 3-Methyladenine (3-MA)可以通过对磷酸肌醇3磷酸激酶(PI3K) 的作用来阻断自吞噬, 而PI3K的活性对于自噬体形成早期膜池的成核和组装是必须的。与SAH 处理组相比3-MA并不会改变出血的程度。与SAH +对照成分组相比经过3-MA预处理后会明显加重神经病学症状。3-MA处理会减少自吞噬发生[5]。 相反地,在SAH + 3-MA组里 断裂的半胱天冬酶表达量明显上调,与此一致的是与SAH + 对照成分组相比,SAH + 3-MA组中右脑皮层里原位末端标记阳性细胞数量明显增多[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[4]
- 合并

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
细胞实验:[2]
- 合并
  • Cell lines: HeLa 细胞系
  • Concentrations: 1-10 mM
  • Incubation Time: 3 分钟
  • Method: 用台盼蓝染色法分析细胞存活率(如HeLa细胞)。简言之, 经过3-MA处理后将贴壁的与漂浮的细胞都用PBS( pH 7.4)重悬,密度控制在每毫升1-2×106。加入等体积的0.4% 台盼蓝并彻底混匀。室温孵育3分钟后用血细胞计数器对细胞计数分析。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 体重 300-350 g 的成年雄性Sprague–Dawley 大鼠
  • Dosages: 400 nM
  • Administration: 脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 10 mg/mL warmed (67.04 mM)
DMSO 3 mg/mL warmed (20.11 mM)
Ethanol ''4 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 149.15
化学式

C6H7N5

CAS号 5142-23-4
储存条件 粉状
溶于溶剂
别名 NSC 66389

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • 回答:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)供应商 | 采购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)价格 | 3-Methyladenine (3-MA)生产 | 订购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID